ISPOR - PDG12 Cost-Effectiveness Analysis of Olaparib for Metastatic Castration Resistant Prostate Cancer Patients with at Least one Mutation in Genes BRCA1, BRCA2, or ATM

PDG12 Cost-Effectiveness Analysis of Olaparib for Metastatic Castration Resistant Prostate Cancer Patients with at Least one Mutation in Genes BRCA1, BRCA2, or ATM

Abstract

Authors

Y. Li X. Huang D. Lin S. Lin X. Weng

Full Text Cite This Article

Back to Volume 24, Supplemental S1

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now